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High-dose Atorvastatin After Stroke or Transient Ischemic Attack
Amarenco P, Bogousslavsky J, Callahan A 3rd, et al; Stroke Prevention by
Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
N Engl J Med 2006;355:549-59.
Conclusion: Patients without known coronary heart disease who have
had a recent stroke or transient ischemic attack (TIA) have a reduction in
overall incidence of stroke and cardiovascular events with 80 mg of atorva-
statin per day.
Summary: It is known statins reduce the risk of stroke in patients at
increased risk for cardiovascular disease. The authors sought to determine
whether there was a reduction in stroke after recent stroke or TIA with the
use of statin medication. This was a randomized double-blind study. Eligible
patients had a stroke or TIA within in 1 to 6 months before study entry.
Low-density lipoprotein (LDL) cholesterol levels were required to be be-
tween 100 to 190 mg/dL. The patients had no known coronary heart
disease. Randomization was to 80mg of atorvastatin per day or placebo. The
primary end point was a first nonfatal or fatal stroke.
During the course or the trial, the mean LDL cholesterol level in
patients receiving atorvastatin was 73mg/dL, and patients receiving placebo
had a mean LDL cholesterol level of 129mg/dL. Median follow-up was 4.9
years. During follow-up, 265 patients (11.2%) receiving atorvastatin and
313 patients (13.1%) receiving placebo had a nonfatal or fatal stroke. This
was an absolute risk reduction of 2.2% (adjusted hazard ratio [HR], 0.84;
95% confidence interval [CI], 0.71 to 0.99; P  .03). The placebo group
had 274 ischemic strokes and 33 hemorrhagic strokes. The atorvastatin
group had 55 hemorrhagic strokes and 218 ischemic strokes. In the patients
receiving atorvastatin, the 5-year absolute risk reduction in the risk of major
cardiovascular events was 3.5% (HR, 0.8; 95% CI, 0.69 to 0.92; P  .002).
Overall mortality was similar between the two groups (P  .98). Rates of
serious adverse events were also similar between the two groups. Elevated
liver enzyme values were more common in patients taking the statin medi-
cation.
Comment: Medications active in reducing cardiovascular end points
should be evaluated with respect to both their primary preventive abilities
(ie, preventing any event) and their secondary preventive abilities (ie, pre-
venting subsequent events in patients with previous events). This article
indicates that statins have both secondary and primary preventive effects in
patients with transient ischemic attacks or strokes. A statin medication
should be strongly considered in a patient who has a history of TIA or
ischemic stroke.
Endovascular Repair For Aorta-Enteric Fistula: A Bridge Too Far Or a
Bridge To Surgery?
Danneelis MIL, Verhaugen HGN, Teijinki JAW, et al. Eur J Endovasc Surg
2006;32:27-33.
Conclusion: Endovascular treatment of aorta-enteric fistula should be
viewed as a temporizing measure before definitive surgical treatment.
Summary: The authors reviewed their endovascular treatment of aor-
ta-enteric fistula (AEF). Between March 1999 and March 2005, 15 patients
in five university hospitals in Belgium and the Netherlands were treated for
AEF by endovascular techniques. The mean age was 67 years, 80% were
men, and 87% had previous aortic or iliac surgery. Prior surgery varied from
1.7 to 307 months before development of aorta-enteric fistula. At the time
of treatment, 53% of patients were in shock and five (33%) had signs of
systemic infection. In eight cases (53%), the treatment was performed as an
emergency. There were 10 aorta uni-iliac devices placed, three aorta bi-iliac
devices placed, one tube graft placed, and 1 patient was treated with
occluding devices only. All received antibiotics for an extended period of
time postoperatively.
The 30-day mortality was zero. All aortic-enteric fistulas were success-
fully sealed. Mean hospital stay was 20 days (range, 2 to 81 days). There was
one death at 2.7 months of postoperative complications and one death
secondary to lung cancer. Four patients are without late signs of infection.
The mean follow-up in these four patients is 15.7 months (range, 1 to 44
months). Nine patients (60%) had recurrent infection or recurrent aortic-
enteric fistula. This occurred after a mean of 9.5 months (range, 0.6 to 31
months). Seven of these patients were reoperated on successfully and two
died.
Comment: Placement of an aortic stent graft for definitive treatment of
aorta-enteric fistula seems like a silly idea. It violates virtually every known
surgical principle. Nevertheless, it does not seem unreasonable to use an
aortic endograft in patients with aortic-enteric fistula as a temporizing
measure. This can serve to convert an emergency to a more elective situation
and should make a high-risk operation safer.
Overweight, Obesity, And Mortality In A Large Prospective Cohort of
Persons 50 To 71 Years Old
Adams KF, Schatzkin A, Harris TB, et al. N Engl J Med 2006;355:763-78.
Conclusion: There is an increased risk of death during mid life from
excess body weight, including patients who are categorized as overweight
but not obese.
Summary: The authors sought to evaluate the risk of death in both
obese and overweight persons. Obesity is defined as a body mass index
(BMI) of 30.0. Persons are classified overweight when their BMI is
between 25.0 and 29.9. The authors studied the relationship between BMI
and risk of death from any cause in 527,265 men and women in the United
States who are enrolled in the National Institutes of Health/AARP Cohort.
All were 50 to 71 years old at the time of enrollment in 1995 through 1996.
Self-reported weight and height were used to calculate BMI. Relative risk of
death was adjusted for age, level of education, smoking status, race or ethnic
group, alcohol intake, and physical activity. Additional analyses were used to
address potential biases secondary to smoking status and chronic disease
existing at the time of enrollment.
There was a maximum follow-up of 10 years that extended through
2005. During follow-up, 61,317 participants died (42,173 men and 19,144
women). There was an increased risk of death among both men and women
in the highest and lowest categories of BMI. This extended to all racial and
ethnic groups and was present at all ages. Restricting analysis to persons who
had never smoked and who were healthy, the risk of death was increased in
both overweight and obese people in both men and women. Analyzing BMI
during mid life (age 50 years) in subjects who had never smoked, the
association between the risk of death and excess body weight showed a 20%
to 40% increase among overweight persons and a two to three times increase
among obese persons. There was also an increased risk of death among
underweight persons, but this was attenuated compared with overweight
persons.
Comment: One of the realities of Western civilization is that people
tend to gain weight as they age. This article and an accompanying article
(N Engl J Med 2006;355:779-87) suggest that even modest weight gains in
middle age are associated with increased mortality. The mechanism for this
increased mortality in overweight but not obese persons is unknown, but is
postulated to be at least partially related to a chronic inflammatory state
secondary to excess adipose tissue. Whatever the cause, it appears that
middle-aged persons will significantly benefit by reversing the tendency for
the weight gain that accompanies aging.
Aneurysm Syndromes Caused By Mutations In The TGF-Beta Receptor
Loeys BL, Schwarze L, Holm T, et al. N Engl J Med 2006; 355:788-98
Conclusion: Mutations in genes encoding transforming growth fac-
tor- (TGF-) receptors 1 and 2 (TGF BR1 and TGF BR2) results in
aggressive and widespread aneurysmal vascular disease.
Summary: Loeys-Dietz syndrome is an autosomal-dominant aortic
aneurysm syndrome that has been recently described. It is characterized by a
triad of hypertelorism, a bi-fed uvula or cleft palate, and arterial tortuosity in
aneurysms. It is caused by heterozygous mutations in genes or coding for
TGF- receptors 1 and 2. Patients with Loeys-Dietz syndrome are at
significant risk of aortic rupture or dissection at a young age with aortic
diameters that would not generally be predictive of such events. Surgical
intervention is usually successful, distinguishing Loeys-Dietz syndrome
from vascular Ehlers-Danlos syndrome.
In this study, the authors studied 52 affected families with Loeys-Dietz
syndrome. Forty probrands had typical manifestation of Loeys-Dietz syn-
drome. Because there is phenotypic overlap between Loeys-Dietz syndrome
and vascular Ehlers-Danlos syndrome, the authors also screened an addi-
tional 40 patients with vascular Ehlers-Danlos syndrome who did not have
the characteristic type 3 collagen abnormalities or the cranial facial features
of Loeys-Dietz syndrome.
There was a mutation in TGF BR1 or TGF BR2 in all probrands with
typical Loeys-Dietz syndrome (type 1). Mutations were also present in 12
probrands presenting with vascular Ehlers-Danlos syndrome (Loeys-Dietz
syndrome type 2). Both type 1 and type 2 Loeys-Dietz syndromes were
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characterized by arterial aneurysms at an early age (mean age at death, 26.0
years). There was also a high incidence of pregnancy-related complications
in 6 of 12 women. Compared with patients with Loeys-Dietz syndrome type
2, those with Loeys-Dietz syndrome type 1 underwent cardiovascular sur-
gery at an earlier age (mean age, 16.9 years vs 26.9 years) and died an earlier
age (22.6 vs 31.8 years). In the 59 surgeries in the cohort of patients studied,
there was only one death during the procedure, distinguishing Loeys-Dietz
syndrome from vascular Ehlers-Danlos syndrome.
Comment:Mutations of genes in coding for TGF- receptors 1 and 2
are associated with a continuum of clinical features, includingmutations that
result inMarfan syndrome, those associated with the Loeys-Dietz syndrome,
and those associated with vascular Ehlers-Danlos syndrome. Given the
different phenotypic characteristics of patients with TGF- receptor
mutations and the potential for pharmacologic manipulation of TGF-
receptors, a study such as this that characterizes phenotype with genotype
is crucial to more precisely target therapy in patients with genetically
based disorders.
Identification Of Patients At Low Risk For Recurrent Venous Throm-
boembolism By Measuring Thrombin Generation
Hron G, Kollars N, Binder BR, et al. JAMA, 2006;296:397-402.
Conclusion: Patients at low risk for recurrent venous thromboembo-
lism (VTE) can be identified by measurement of thrombin generation.
Summary: Patients with VTE are often investigated for thrombophilic
risk factors. The large number of potential thrombophilic risk factors makes
this complex and expensive. The authors sought to determine whether the
risk of recurrent VTE could be assessed by a global coagulation assay that
measures thrombin generation.
This was a prospective cohort study of 914 patients. All patients had a
spontaneous VTE and were followed for an average of 47 months after
discontinuation of oral anticoagulant therapy. The study period was from
July 1992 to July 2005. A commercially available assay was used to measure
thrombin generation. Excluded patients included those with secondary
VTE, those with recurrent VTE, or those with a known thrombophilic risk
factor such as antithrombin, protein C or protein S deficiencies, the presence
of lupus anticoagulant, or cancer or pregnancy. The primary outcome
measure was an objectively documented episode of recurrent VTE.
VTE recurred in 100 patients (11%). There was lower thrombin
generation in the patients without recurrent VTE compared with those with
recurrent VTE (349.2 108 nN vs 415 110.5 nN, P .001). In patients
with thrombin generation values between 400 nN and 300 nN, the
relative risk of recurrence compared to patients with thrombin genera-
tions 400 nN was 0.42 (95% confidence interval [CI], 0.26 to 0.67, P
 .001). In patients with measured thrombin generations 300 nN
relative risk was 0.37 (95% CI, 0.21 to 0.66, P  .001). For 4 years, the
probability of VTE recurrence in patients with thrombin generation
400 nN was 6.5% (95% CI, 4.0% to 8.9%). In those patients with
thrombin generation values400, the probability of VTE recurrence was
20.0% (95% CI, 14.9% to 25.1%, P  .001). Patients with thrombin
generation400 nN had a 60% lower recurrence of VTE than those with
greater values of thrombin generation (relative risk, 0.40; 95% CI, 0.27
to 0.60; P  .001.
Comment:There are data to suggest that patients with idiopathic VTE
benefit from longer periods of anticoagulation than those with VTE and a
recognizable risk factor such as surgery or trauma. Given the implications of
long-term anticoagulant therapy, it is desirable to identify which patients
with idiopathic VTE are particularly prone to recurrence. If this study can be
confirmed by others, measurement of thrombin generation may prove to be
a relatively simple method of stratifying patients for their length of antico-
agulation after a first time episode of idiopathic VTE.
An Audit Demonstrating A Reduction In MRSA Infection In A Spe-
cialised Vascular Unit Resulting From A Change In Infection Control
Protocol
Thompson M. Eur J Vasc Endovasc Surg 2006;31:609-15.
Conclusion: Changes in infection control policy can markedly reduce
MRSA infection in a vascular surgery unit.
Summary:Methicillin-resistant Staphylococcus aureus (MRSA) is most
often a hospital-acquired infection. Rates of infection are continuing to rise
worldwide. It has become the singlemost common organism associated with
complex wound and graft infections after vascular surgery. (Eur J Vasc
Endovasc Surg, 2001;21:289-94). The author sought to evaluate if changes
in infection control policies could reduce MRSA infection in their vascular
surgical unit.
In the author’s vascular surgical ward in 2003, 18% of admissions were
colonized by MRSA. There was a 10.6% MRSA infection rate at that time.
Practice at that point was to segregate patients with proven MRSA from the
rest of the patients on the ward. The author performed a prospective audit
using regression analysis to identify factors that may stratify patients into low
and high risk for MRSA colonization. An isolation policy was then intro-
duced to segregate patients according to their risk of MRSA acquisition. All
patients undergoing prosthetic vascular reconstruction were isolated. In
addition, antibiotic policy was also altered. The MRSA status of 777 inpa-
tients was evaluated and data were prospectively recorded during three time
spans. Period 1 was November 2002 through April 2003, the period before
the change in isolation and antibiotic policy. Period 2 was August 2003
through December 2003, and period 3 was October 2004 through January
2005, after the changes in infection control policy.
In period 1, hospital acquiredMRSA colonization was 10.6%. This was
reduced to 1.1% and 1.4% in periods 2 and 3, respectively (P .001).MRSA
infection rates also fell from 10.6% in period 1 to 2.9% and 0.9% over the
same time frame (P  .01). Changes in MRSA infection rates were most
pronounced in patients undergoing aneurysm repair (MRSA infection,
30.1% in period 1 vs 3.9% and 2.9% in periods 2 and 3) and lower limb
revascularization (31% vs 0% vs 4.2%). Regression analysis indicated that the
isolation system was a significant factor in reducing MRSA infection and
colonization rates (P  .001).
Comment: This study was performed in a hospital where vascular
surgical patients were housed in multipatient rooms; therefore, it may not
apply to many US hospitals where many patients have individual rooms.
Nevertheless, the idea of identifying patients at risk for MRSA infection and
instituting infection control policies based on risk rather than on actual
infection is interesting and indicates a proactive approach to this difficult
problem. It is certainly possible that even in hospitals with individual patient
rooms, a policy of increased contact precautions in patients at risk of MRSA
infection may prove worthwhile.
Mortality In Cardiac And Vascular Outcomes In Extremely Obese
Women
McTigue K, Larson JC, Valoski A, et al. JAMA, 2006;296:79-86.
Conclusion: Weight related health risk varies with degree of excess
weight and is independent of race, smoking status, education, United States
region, and physical activity level.
Summary: Obesity is defined as a body mass index (BMI) of 30.
There are three categories of obesity: obesity 1 (BMI, 30 to 34.9), obesity 2
(BMI, 35 to 39.9), and extreme obesity (BMI,40). The latter category
of extreme obesity is increasing rapidly in the United States, particularly
in women. The prevalence of women with a BMI of50 has increased by
five times over the period of 1986 to 2000 (Arch Intern Med 2003;163:
2146-8).
The authors sought to examine the health risks of extreme obesity and
to determine how cardiovascular and mortality risks differ across clinical
weight categories in women. Patients were recruited from 40 US centers
involved in the Women’s Health Initiative Observational Study. From this
study, 90,185 women were examined for incident mortality and cardiovas-
cular outcomes and stratified according to weight status. Patients were
followed up for an average of 7.0 years, fromOctober 1, 1993 to August 31,
2004. The main outcome measures included mortality, incidents of coro-
nary heart disease, diabetes, and hypertension, stratified according to obesity
class with a focus on extreme obesity.
The prevalence of extreme obesity varied with race and ethnicity. The
incidence was 1% in Asian and Pacific Islanders and increased to 10% among
black women. For patients with a body mass index within the normal range,
the all-cause mortality rate per 10,000 person-years was 68.39 (95% confi-
dence interval [CI], 65.26 to 71.68). For patients considered overweight
but not obese, all-cause mortality rate was 71.16 (95% CI, 67.68 to 74.82).
The all-cause mortality rates were 84.47 (95% CI, 78.90 to 90.42) for
obesity category 1, 102.85 (95% CI, 92.9 to 113.86) for obesity category 2,
and 116.85 (95% CI, 103.36 to 132.11) for extreme obesity.
Adjustments for age, smoking, educational achievement, US region,
and physical activity indicated all-cause mortality, coronary heart disease
mortality, and coronary heart disease incidents were not affected by race or
ethnicity. There were positive trends in all-cause mortality and coronary
heart disease incidents with increasing weight category among both white
and black participants in the study. Most of the obesity-related mortality and
coronary heart disease risks were mediated by hyperlipidemia, hypertension,
and diabetes. Weight-related all-cause mortality was modified by age in
white women, with obesity conferring less risk among older white women.
Comment: In my hospital, it seems that there is a 300-pound person in
every elevator. The obesity epidemic is well established. To those of us who
take care of patients, it is not surprising that mortality risks can be stratified
by level of obesity. Overweight—but not obese—women may be initially
comforted by the fact that overweight was not associated with increased
mortality in this study. However, overweight was associated with increased
risk of coronary heart disease incidents, and there certainly is considerable
mortality and morbidity associated with coronary heart disease. It may be
that the 7-year period of observation in this study is insufficient to detect the
long-term health effects of just being overweight but not obese.
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